Palvella director granted 3,000 stock options
PALVELLA THERAPEUTICS, INC. director John Doux received a grant of stock options covering 3,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PALVELLA THERAPEUTICS, INC. director John Doux received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of 102.1900 per share and expire on 2036-06-10.
These options vest upon the earlier of the first anniversary of the 2026-06-10 grant date or the company’s next annual stockholder meeting, subject to his continued service. Following this compensation-related grant, Doux holds 3,000 stock options directly.
Insider Trade Summary
Grant/Award: 3,000 shares
Grant/Award
1 txn
Insider
Doux John
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 3,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.
Key Figures
Options granted: 3,000 options
Exercise price: 102.1900 per share
Expiration date: 2036-06-10
+2 more
5 metrics
Options granted
3,000 options
Stock Option (Right to Buy) granted 2026-06-10
Exercise price
102.1900 per share
Conversion or exercise price of granted options
Expiration date
2036-06-10
Options expiration
Underlying shares
3,000 shares
Common stock underlying the granted options
Holdings after grant
3,000 options
Total derivative holdings following transaction
Key Terms
Stock Option (Right to Buy), grant/award acquisition, exercise price, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
exercise price financial
"conversion_or_exercise_price: "102.1900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-10T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Palvella Therapeutics (PVLA) report for John Doux?
Palvella Therapeutics reported that director John Doux received a grant of stock options for 3,000 shares of common stock. The award is a compensation-related grant, not an open-market purchase or sale, and increases his derivative holdings in the company.
What are the key terms of John Doux’s new stock options at Palvella Therapeutics (PVLA)?
John Doux’s stock options cover 3,000 shares of Palvella Therapeutics common stock at a 102.1900 exercise price, expiring on 2036-06-10. These options give him the right to buy shares at that price once they vest and remain outstanding until expiration.
When do John Doux’s Palvella Therapeutics (PVLA) stock options vest?
The options vest on the earlier of the first anniversary of the 2026-06-10 grant date or the next annual meeting of stockholders following that date. Vesting in both cases requires John Doux to continue serving the company through the applicable vesting date.
Is John Doux’s Palvella Therapeutics (PVLA) Form 4 transaction a market buy or sell?
The Form 4 shows a grant of stock options to John Doux, classified as a grant or award acquisition. It is not an open-market buy or sell, but a compensation-related derivative award that increases his potential future equity exposure to the company.
How many Palvella Therapeutics (PVLA) options does John Doux hold after this grant?
After this grant, John Doux directly holds 3,000 stock options linked to Palvella Therapeutics common stock. These options are exercisable for 3,000 underlying shares once vested and remain outstanding until their stated expiration date in 2036, barring other changes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates